Align Technology
ALGN
$165.98
-1.39%
Align Technology is the global leader in clear orthodontic aligners, manufacturing the Invisalign system and iTero intraoral scanners that digitize dental impressions and treatment planning for a network of more than 230,000 trained dentists and orthodontists. The company operates a dominant, brand-anchored platform in the medical devices space, with Invisalign treating roughly 2 million cases annually (about 10% of global orthodontic cases) and over 20 million patients treated since launch, giving it a scale and clinical-data moat that smaller clear-aligner entrants struggle to replicate. The current investor debate centers on whether Align can reaccelerate growth after a stretch of sluggish consumer dental demand and margin pressure, with the narrative sharpened by activist investor Elliott Management reportedly building a large position in early 2026 as a catalyst to unlock value in a stock trading well below its historical multiples. Recent quarterly results show modest revenue growth (roughly 2% year-over-year) alongside improving profitability and a sharp post-earnings stock reaction, keeping the focus on whether margin recovery and case-volume stabilization can sustain the re-rating.…
ALGN
Align Technology
$165.98
Related headlines
Investment Opinion: Should I buy ALGN Today?
Rating: Hold with a modest positive skew. The core thesis is that Align is a high-quality, cash-generative clear-aligner monopolist trading near the bottom of its multi-year valuation band (2.81x sales, 13.70x forward PE) while revenue growth has stalled at 1.92% year-over-year — a setup where the downside is cushioned by a fortress balance sheet and $602.5 million in trailing free cash flow, but the upside requires case-volume reacceleration that has not yet materialized. The analyst consensus of "buy" (7 Buy, 8 Hold, 1 Sell) with an average target of $185.79 implies +10.4% upside, but the recommendation mean of 2.31 and two recent downgrades (Baird, Evercore ISI) argue that conviction is thinner than the label suggests.
Supporting evidence is genuinely two-sided. On valuation, the forward PE of 13.70x against a trailing 27.59x implies the market expects earnings to roughly double toward the consensus EPS of $15.05, and 13.7x sits well below the high-teens-to-low-20s typical for profitable medtech — a meaningful discount for a franchise with 68.3% gross margins. Profitability is inflecting: operating margin rebounded from 9.67% in Q3 2025 to 16.67% in Q3 2026 and net income jumped from $56.8 million to $135.0 million, while gross margin held at 68.73%. The balance sheet is pristine (debt-to-equity 0.028, $1.146 billion cash) and management repurchased $103.1 million of stock in Q3 2026 alone, accretive at these multiples. Against that, revenue of $1.015 billion grew just 1.92% and declined sequentially from Q2's $1.056 billion, and the PS ratio's collapse from 50.20x in Q4 2021 to 2.81x today is either deep value or a correct repricing of a decelerating growth story.
Three risks could invalidate the thesis: (1) Invisalign case volumes fail to reaccelerate, keeping revenue near the $1.0-$1.05 billion quarterly plateau and making the $15.05 consensus EPS unreachable; (2) gross margin slips back toward the Q2 2026 level of 65.14%, eroding the operating-leverage story; and (3) the Elliott activist campaign stalls without a credible margin or capital-allocation plan, removing the re-rating catalyst. This Hold would upgrade to Buy if forward PE stays below 15x while quarterly revenue growth reaccelerates above 5% and operating margin holds above 16%, or downgrade to Sell if revenue growth turns negative or gross margin breaks below 65%. Net verdict: the stock is undervalued relative to its own history and modestly cheap versus medtech peers, but fairly valued relative to its current stagnant growth trajectory — a value-with-a-catalyst situation rather than a clean bargain.
Sign up to view all
ALGN 12-Month Price Forecast
Align presents a classic deep-value-versus-deceleration debate: a dominant franchise with 68.3% gross margins, near-zero leverage, and $602.5 million in trailing free cash flow trades at 2.81x sales and 13.70x forward earnings, near the bottom of its multi-year valuation band. The margin-recovery story is real — operating margin nearly doubled year-over-year and net income more than doubled to $135.0 million — but the top line has stalled at roughly 2% growth, and the Street's 2.31 recommendation mean with Baird and Evercore downgrades suggests the November rally has outrun fundamentals. The Elliott activist stake is a credible catalyst given the margin and capital-allocation levers available, but it is not a substitute for case-volume reacceleration. I would upgrade to bullish if quarterly revenue growth inflects above 5% with operating margin holding above 16.5%, and downgrade to bearish if gross margin breaks below 65% or revenue turns negative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Align Technology's 12-month outlook, with a consensus price target around $185.79 and implied upside of +11.9% versus the current price.
Average Target
$185.79
16 analysts
Implied Upside
+11.9%
vs. current price
Analyst Count
16
covering this stock
Price Range
$160 - $210
Analyst target range
Coverage is moderate with 14 analysts: 7 Buy, 8 Hold, and 1 Sell, yielding a consensus recommendation of "buy" but a recommendation mean of 2.31 (closer to Hold on a 1-5 scale), indicating a cautiously constructive but divided Street. The average target price of $185.79 implies roughly +10.4% upside from the current $168.32, a modest but positive signal that aligns with the neutral-to-bullish tilt. Consensus revenue estimates of $4.685 billion and EPS estimates of $15.05 suggest analysts expect meaningful earnings recovery even as top-line growth remains subdued.
The target range of $160.00 to $210.00 is moderately wide, with the low target essentially at the current price (implying no upside) and the high target of $210.00 — above the 52-week high of $200.44 — pricing in multiple expansion and successful execution of the margin-recovery and activist-value-unlock thesis. The low end of $160.00 reflects skepticism about growth reacceleration and continued consumer dental softness. Institutional ratings show recent deterioration in sentiment: Baird downgraded from Outperform to Neutral on October 15 and Evercore ISI moved from Outperform to In Line on October 5, while Morgan Stanley, UBS, and others remain at Equal Weight/Neutral — a pattern of fading bullishness that tempers the consensus "buy" label and suggests the post-earnings rally may be running ahead of analyst conviction.
Bulls vs Bears: ALGN Investment Factors
The bear case currently has slightly stronger near-term evidence: revenue growth of just 1.92% year-over-year, a recommendation mean of 2.31, and two recent downgrades argue that the November rally has outrun fundamentals. However, the bull case is structurally compelling — a 13.70x forward PE against 68.73% gross margins, $602.5 million in trailing free cash flow, near-zero leverage, and an Elliott activist catalyst create a classic deep-value setup. The single most important tension is whether Invisalign case volumes reaccelerate enough to justify the consensus EPS of $15.05; if they do, the forward multiple re-rates sharply, but if stagnation persists, the low target of $160.00 caps the upside. On balance, the risk/reward skews modestly positive given the valuation floor and margin recovery, but conviction is medium rather than high.
Bullish
- Forward PE of 13.7x is deeply discounted: The forward PE of 13.70x versus a trailing PE of 27.59x implies the market expects earnings to roughly double, yet 13.7x is well below the high-teens-to-low-20s typical for profitable medtech. With consensus EPS of $15.05 against trailing EPS of $0.036, the earnings recovery is already embedded in estimates, making the multiple look like a mispricing rather than a warning.
- Margin recovery is real and accelerating: Operating margin rebounded from 9.67% in Q3 2025 to 16.67% in Q3 2026, and net income jumped from $56.8 million to $135.0 million over the same period. Gross margin held at 68.73% in Q3 2026, consistent with the 65%-71% band, confirming the cost-discipline story is translating into bottom-line leverage.
- Fortress balance sheet with heavy buybacks: Debt-to-equity is just 0.028 with $1.146 billion in cash and trailing free cash flow of $602.5 million. Align repurchased $103.1 million of stock in Q3 2026 alone, which is highly accretive at a 2.81x PS ratio and signals management conviction in the undervaluation.
- Activist catalyst from Elliott Management: Elliott Management reportedly built a large position in early 2026, and the stock jumped on the news, providing a concrete value-unlock catalyst for a franchise trading near the bottom of its multi-year valuation band. Activist pressure on a company with 68.3% gross margins and a dominant 10% share of global orthodontic cases has a credible path to margin and capital-allocation improvements.
Bearish
- Revenue growth has stalled near 2%: Q3 2026 revenue of $1.015 billion grew just 1.92% year-over-year, and the sequential trend is flat-to-down from Q2's $1.056 billion and Q1's $1.040 billion. The core Invisalign franchise at $794.3 million is carrying the growth burden while the business stagnates around the $1.0-$1.05 billion quarterly level.
- Analyst sentiment is deteriorating: Baird downgraded from Outperform to Neutral on October 15 and Evercore ISI moved from Outperform to In Line on October 5, leaving 8 Hold and 1 Sell against 7 Buy. The recommendation mean of 2.31 sits closer to Hold than Buy, suggesting the post-earnings rally is running ahead of analyst conviction.
- Valuation history shows persistent compression: The PS ratio has collapsed from 50.20x in Q4 2021 and 24.09x in Q1 2024 to just 2.81x today, while PE fell from 67.89x to 27.59x trailing. This multi-year de-rating either signals genuine value or reflects fundamental deterioration in the growth story that the market has correctly priced.
- High volatility and violent drawdowns: Beta of 1.738 makes Align roughly 74% more volatile than the market, and the 29.18% maximum drawdown over the trailing period underscores how violent the swings have been. The stock twice sold off hard from the $180-$188 zone before finding buyers near $140-$145, showing resistance is well entrenched.
ALGN Technical Analysis
Align is in a choppy but net-positive recovery trend: the stock is up 20.73% over the trailing year and 7.88% year-to-date, and at $168.32 it sits roughly 54.6% of the way through its 52-week range of $130.23 to $200.44. That mid-range positioning reflects a stock that has recovered meaningfully off its lows but has repeatedly failed to reclaim its highs, suggesting neither a clean momentum breakout nor a falling-knife setup. The 29.18% maximum drawdown over the period underscores how violent the swings have been, with the stock twice selling off hard from the $180-$188 zone before finding buyers near $140-$145.
Short-term momentum has turned sharply positive and is diverging from the medium-term trend: the stock is up 16.53% over the past month versus a 7.16% decline over three months, a classic V-shaped reversal. That one-month surge produced a relative strength reading of +18.79 versus the S&P 500 (which fell 2.26% over the same month), and the move accelerated after the November 4 earnings filing, with the stock gapping from $151.58 to $164.90 in a single session and touching $174.26 by November 9. The three-month relative strength of -4.33 versus SPY confirms the stock lagged into the fall before this sharp snapback, so the current rally is a mean-reversion recovery rather than a continuation of an established uptrend.
Key technical levels are well defined: support sits at the 52-week low of $130.23, with a secondary floor around $140-$145 where the stock based in October, while resistance is the 52-week high of $200.44, with an intermediate ceiling at the $180-$188 area that capped rallies in July and August. A decisive break above $188 would signal a genuine trend change and open the path toward the $200 high, whereas a failure here and a slide back below $150 would suggest the post-earnings pop is fading. With a beta of 1.738, Align is roughly 74% more volatile than the market, meaning position sizing should account for amplified drawdowns — the 29.18% max drawdown is a realistic stress-case guide, and a short ratio of 4.06 days indicates moderate short interest that can add fuel to rallies or accelerate selloffs.
Beta
1.74
1.74x market volatility
Max Drawdown
-29.2%
Largest decline past year
52-Week Range
$130-$200
Price range past year
Annual Return
+21.0%
Cumulative gain past year
| Period | ALGN Return | S&P 500 |
|---|---|---|
| 1m | +12.7% | -3.0% |
| 3m | -1.1% | -3.6% |
| 6m | +1.6% | -0.2% |
| 1y | +21.0% | +10.1% |
| ytd | +6.4% | +8.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALGN Fundamental Analysis
Revenue growth has decelerated to a crawl: Q3 2026 revenue of $1.015 billion grew just 1.92% year-over-year against $995.7 million in Q3 2025, and the sequential trend is flat-to-down from Q2's $1.056 billion and Q1's $1.040 billion. The revenue mix shows clear aligners at $794.3 million and scanners/services at $200.9 million, meaning the core Invisalign franchise — the bulk of the business — is carrying the growth burden while the smaller iTero segment provides a steadier digital-platform anchor. The multi-quarter picture (Q4 2025: $1.048 billion; Q1 2026: $1.040 billion; Q2 2026: $1.056 billion; Q3 2026: $1.015 billion) is one of stagnation around the $1.0-$1.05 billion quarterly level, which is the central bear argument and the reason activist pressure has emerged.
Profitability is solid and improving at the operating line: Q3 2026 net income was $135.0 million on a 13.31% net margin, with gross margin of 68.73% and operating margin of 16.67%, up from Q3 2025's much weaker $56.8 million net income and 5.70% net margin. Gross margin has been relatively stable in the 65%-71% band over the past several quarters (Q1 2026: 70.82%; Q2 2026: 65.14%; Q3 2026: 68.73%), consistent with the high-gross-margin profile typical of premium medical-device franchises, while the operating margin recovery from 9.67% in Q3 2025 to 16.67% in Q3 2026 reflects cost discipline and operating leverage returning. The Q2 2026 dip in gross margin to 65.14% and operating margin to 11.67% shows the business is not immune to quarterly cost volatility, but the Q3 rebound supports the margin-recovery thesis.
Financial health is excellent: debt-to-equity is just 0.028, the current ratio is 1.36, and trailing free cash flow is $602.5 million, with Q3 2026 FCF of $137.9 million generated from $182.9 million in operating cash flow against $45.0 million of capex. The company holds $1.146 billion in cash and is actively returning capital, repurchasing $103.1 million of stock in Q3 2026 alone, which is highly accretive at current valuations. ROE of 10.13% and ROA of 8.01% are respectable but below the company's historical peaks, and the near-zero leverage means Align funds growth and buybacks internally rather than depending on external financing — a low financial-risk profile that provides a cushion if growth remains sluggish.
Quarterly Revenue
$1.0B
2026-09
Revenue YoY Growth
+1.9%
YoY Comparison
Gross Margin
68.7%
Latest Quarter
Free Cash Flow
$602500000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALGN Overvalued?
Because Align is profitable (Q3 2026 net income of $135.0 million), the PE ratio is the appropriate primary metric. The trailing PE is 27.59x versus a forward PE of just 13.70x, an unusually wide gap that implies the market expects earnings to roughly double — consistent with consensus EPS estimates of $15.05 versus the current trailing EPS of $0.036 (a figure distorted by quarterly volatility and likely non-GAAP adjustments). The forward multiple of 13.7x is remarkably cheap for a high-gross-margin medical-device leader, suggesting either significant skepticism about the earnings trajectory or a mispricing that the activist narrative is trying to close.
On peer-relative metrics, Align trades at a PS ratio of 2.81x and EV/Sales of 2.61x, with EV/EBITDA of 12.60x and a PCF ratio of 19.09x — multiples that look modest for a franchise with 68.3% gross margins and a dominant market position. The PEG ratio of 51.77 is an outlier that reflects near-zero trailing earnings growth rather than a true growth-adjusted valuation, so it should be discounted; the more telling comparison is the forward PE of 13.7x against the sector's typical high-teens-to-low-20s range for profitable medtech, implying Align trades at a meaningful discount to its quality. The premium embedded in the 2.81x PS is modest relative to Align's historical norms, reinforcing the view that the market is pricing in stagnation rather than the company's structural advantages.
Historical context is striking: Align's PS ratio has compressed from 50.20x in Q4 2021 and 24.09x in Q1 2024 to just 2.81x today, while its PE has fallen from 67.89x in Q4 2021 to 27.59x trailing and 13.70x forward. The stock is near the bottom of its own multi-year valuation band on both sales and earnings multiples, which either signals a genuine value opportunity (if margins and growth stabilize) or reflects fundamental deterioration in the growth story. Given the improving Q3 margins, fortress balance sheet, and activist catalyst, the historical-low valuation skews toward opportunity, though the market will demand evidence of reaccelerating case volumes before re-rating the stock toward its former multiples.
PE
27.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 19x~98x
vs. Industry Avg
26.4x
Industry PE ~26.4x*
EV/EBITDA
12.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the stalled top line and dependence on margin recovery to justify the earnings estimate. Revenue grew only 1.92% year-over-year in Q3 2026 to $1.015 billion, and the sequential trend is flat-to-down from Q2's $1.056 billion, meaning the consensus EPS of $15.05 requires operating leverage rather than growth. Gross margin has shown quarterly volatility, dipping to 65.14% in Q2 2026 before rebounding to 68.73%, and the core Invisalign segment at $794.3 million represents roughly 78% of revenue, creating concentration risk in a single product line exposed to discretionary consumer dental spending. The cushion is real — debt-to-equity of 0.028, $1.146 billion in cash, and $602.5 million in trailing free cash flow — but ROE of 10.13% remains below historical peaks, and the PEG ratio of 51.77 reflects near-zero trailing earnings growth.
Market and competitive risks are dominated by valuation compression and fading analyst conviction. The stock trades at 2.81x sales and 12.60x EV/EBITDA, near the bottom of its own multi-year band, but that discount can persist if growth does not reaccelerate; the PS ratio has fallen from 50.20x in Q4 2021 to 2.81x today. With a beta of 1.738, Align is roughly 74% more volatile than the market, amplifying any sector rotation out of medtech or consumer-discretionary-adjacent names. Recent downgrades from Baird (October 15) and Evercore ISI (October 5) to Neutral/In Line, alongside a recommendation mean of 2.31, show the Street is trimming exposure, and peer commentary on soft dental demand (XRAY's Q2 margin compression) suggests the headwind is industry-wide rather than company-specific.
The worst-case scenario is a consumer dental recession combined with failed activist execution: case volumes stagnate, gross margin slips back toward the 65% Q2 level, and the consensus EPS of $15.05 proves unreachable, forcing multiple compression toward the low end. In that chain, the stock would retest its 52-week low of $130.23, a decline of roughly -22.6% from the current $168.32, and a repeat of the 29.18% maximum drawdown would take the shares to approximately $119. A slide back below the $140-$145 October base would confirm the post-earnings pop has faded and open the path toward the $130 floor, with the analyst low target of $160.00 offering little protection in a genuine de-rating.
FAQ
Ranked by severity, the first risk is company-specific growth stagnation: Q3 2026 revenue of $1.015 billion grew just 1.92% year-over-year and declined sequentially from Q2's $1.056 billion, with the core Invisalign segment at $794.3 million representing roughly 78% of revenue — a single-product concentration in discretionary consumer dental spending. Second is financial/margin risk: gross margin swung from 70.82% in Q1 2026 to 65.14% in Q2 before rebounding to 68.73%, and a break below 65% would make the $15.05 consensus EPS unreachable and undercut the entire operating-leverage thesis. Third is market/valuation risk: with a beta of 1.738, ALGN is roughly 74% more volatile than the market, and the 29.18% max drawdown shows how violently it de-rates during sector rotation out of medtech; the PS compression from 50.20x to 2.81x could extend rather than reverse. Fourth is catalyst/execution risk: the Elliott Management campaign could stall or turn into a disruptive proxy fight, and analyst conviction is already thinning with 8 Hold and 1 Sell against 7 Buy and a recommendation mean of 2.31.
The 12-month forecast is split across three scenarios. The base case (50% probability, $175-$190) assumes revenue growth grinds to 3-5%, gross margin holds at 66-69% and operating margin at 15-17%, and the stock drifts toward the $185.79 analyst average as the forward multiple modestly re-rates from 13.70x. The bull case (25%, $200-$210) requires Invisalign case volumes inflecting above 5% year-over-year, operating margin sustaining above 16.5%, and Elliott formalizing board seats or a strategic review, pushing shares past the $200.44 52-week high toward the $210 analyst high target. The bear case (25%, $130-$160) assumes consumer dental softness persists, gross margin slips toward the 65.14% Q2 level, and the stock retests the $140-$145 October base and then the $130.23 52-week low. The base case is most likely, and its key assumption is that margin recovery — not revenue growth — carries earnings toward $15.05; the probabilities sum to 100%.
On the primary metric, ALGN screens undervalued relative to its own history and modestly cheap versus profitable medtech peers. The forward PE of 13.70x sits well below the high-teens-to-low-20s typical for high-gross-margin device franchises, and the trailing PE of 27.59x versus forward 13.70x implies the market expects earnings to roughly double toward the $15.05 consensus EPS. The PS ratio of 2.81x and EV/EBITDA of 12.60x are near the bottom of a multi-year band that once saw PS at 50.20x in Q4 2021 and 24.09x in Q1 2024, while PCF of 19.09x and PB of 2.80x are unremarkable for a company with 68.3% gross margins. The caveats are that the PEG ratio of 51.77 reflects near-zero trailing earnings growth, and the 13.7x forward multiple is only cheap if the $15.05 EPS estimate is achievable — which requires operating leverage on a flat top line. The market is therefore pricing stagnation, not structural decline; if case volumes reaccelerate, the multiple has room to re-rate, but if growth stays near 2%, 13.7x is arguably fair rather than cheap.
The risk/reward is modestly favorable but not compelling enough for a clean Buy. At $168.32, the stock offers roughly +10.4% upside to the $185.79 average analyst target and +24.7% to the $210 high target, while the $160 low target implies only about -4.9% downside and the 52-week low of $130.23 marks a -22.6% worst case. The valuation support is genuine — 13.70x forward earnings against 68.3% gross margins, $602.5 million in trailing free cash flow, and debt-to-equity of 0.028 — but revenue growth of just 1.92% year-over-year and a recommendation mean of 2.31 with two recent downgrades (Baird, Evercore ISI) mean the catalyst has to come from margin execution or Elliott-driven action rather than organic momentum. It is a reasonable buy for value-oriented investors with a 12-18 month horizon who can tolerate a beta of 1.738 and a 29.18% max drawdown, particularly on pullbacks toward the $140-$150 base; it is a poor fit for momentum or income investors, since the dividend yield is 0% and the stock has repeatedly failed at $180-$188.
ALGN is better suited to a medium-to-long-term holding period of at least 12-18 months than to short-term trading. The company is in a mature-growth-to-turnaround phase: revenue is flat near $1.0-$1.05 billion per quarter, but operating margin recovered from 9.67% to 16.67% year-over-year and free cash flow of $602.5 million funds $103.1 million of quarterly buybacks, which is a slow-burn value-unlock story rather than a momentum trade. The beta of 1.738 and 29.18% max drawdown make short-term positioning hazardous — the stock gapped from $151.58 to $164.90 in a single session on November 4 and has swung between $130.23 and $200.44 over the trailing year. There is no dividend (yield 0%, payout ratio 0), so total return depends entirely on price appreciation and buyback accretion, and earnings visibility is only moderate given the 1.92% revenue growth and divided analyst coverage. A patient investor with a 12-18 month horizon can underwrite the Elliott catalyst and margin recovery; anyone trading the next few weeks is effectively betting on whether the $180-$188 resistance breaks.

